stock-detail (THLD)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

World Health Organization Drops Coffee’s Status as Possible Carcinogen

6/15/2016 11:05 am

(Wall Street Journal) June 15, 2016 - Twenty-five years after classifying coffee as a possible carcinogen leading to bladder cancer, the World Health Organization’s cancer research arm has reversed course, saying on Wednesday that coffee is not classifiable as a carcinogen.

One-Third of Clinical Trial Results Never Disclosed, Study Finds

2/18/2016 12:03 pm

(Bloomberg) Feb 17, 2016 - One-third of clinical trials conducted at 51 major U.S. universities and academic hospitals were never published in a peer-reviewed journal or in a government registry online, according to a new study in the BMJ, formerly the British Medical Journal.

FDA Sees Spike in Gene and Cell Therapy Applications

2/17/2016 12:01 pm

( Feb 16, 2016 - The US Food and Drug Administration’s Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) met Tuesday to discuss updates of research programs in the Office of Cellular, Tissue and Gene Therapy (CTGT), which is part of FDA’s Center for Biologics Evaluation and Research (CBER).

Shopping for a Doctor Who ‘Fits’

7/27/2015 12:00 pm

(New York Times/Well blog) July 23, 2015 - Decades ago, when physicians worked within a much more paternalistic system, “doctor shopping” by patients would have been considered inappropriate. Now it has become a routine part of my practice.

New Drug Sharply Lowers Cholesterol, but It’s Costly

7/27/2015 12:00 pm

(New York Times) July 24, 2015 - Federal regulators on Friday approved the first of a new class of drug that can sharply lower cholesterol levels, offering a new option for millions of Americans suffering from cardiovascular disease, the nation’s leading killer.

FDA Strengthens Heart Safety Warnings on Painkillers

7/10/2015 11:04 am

(NBC News) July 9, 2015 - The Food and Drug Administration is strengthening its warnings about painkillers like ibuprofen, saying they do raise the risk of heart attack or stroke.

Celldex Builds Case for Brain Cancer Vaccine With New ASCO Data

5/31/2015 07:01 pm

(Xconomy New York) May 31, 2015 - Celldex Therapeutics grabbed the spotlight late last year when an experimental vaccine it’s been developing helped extend the lives of some patients with an aggressive, deadly form of brain cancer.

Biocept’s Blood-based Liquid Biopsy for Non-small Cell Lung Carcinoma Highlighted in American Society of Clinical Oncology (ASCO) Abstract

5/28/2015 12:02 pm

(StreetInsider) May 28, 2015 - Biocept, Inc., a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, continues to build evidence of the clinical utility of its liquid biopsy offerings with an abstract at the 2015 Annual American Society of Clinical Oncology Meeting in Chicago starting on May 29, 2015.

Exercise Offers Cancer Survivors Significant Improvements in Quality of Life

5/28/2015 12:02 pm

(Yale News) May 28, 2015 - For many cancer survivors, a better quality of life is as close as the nearest pair of sneakers. That’s because a growing body of research, including two recent studies led by Yale Cancer Center, show that exercise is a powerful way for survivors to improve quality of life.

A More Effective Shingles Vaccine Could Be on the Way for People Who Need It Most — Seniors

4/29/2015 12:00 pm

(Washington Post) Apr 28, 2015 - GSK says new shingles vaccine shows effectiveness across all age ranges, even those in their 70s.

New Breath Test Detects Stomach Cancer

4/14/2015 12:00 pm

( Apr 14, 2015 - Scientists have discovered a new type of technology that senses compounds in exhaled breath that can be used as a screening tool to detect stomach cancer.

Novartis Accelerates Cancer Immunotherapy Efforts with Aduro Biotech Alliance and Launch of New Immuno-oncology Research Group

3/30/2015 06:04 am

(Novartis) Mar 30, 2015 - Novartis announced today that it is stepping up its efforts to harness the body's immune system to combat cancer. The company has entered into a major multiyear alliance with Aduro Biotech that is focused on the discovery and development of next generation cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway and launched a new immuno-oncology research group led by renowned cancer vaccine expert Glenn Dranoff, MD.

Cancer Immunotherapy 'Has Entered Mainstream'

3/26/2015 11:05 am

(Medscape Medical News) Mar 25, 2015 - Cancer immunotherapy takes centre stage in a series of articles about harnessing the immune system for therapy published March 25 as a special issue of Science Translational Medicine.

Lawmakers Said to Seek Medicare Fee Changes

3/16/2015 07:00 am

(Bloomberg) Mar 13, 2015 - The doctors who treat Medicare patients would avoid a cut in their government reimbursements under a proposal to be presented to U.S. House members next week, according to Republican and Democratic aides.

NCCN Recommends Only One Genomic Test For Breast Cancer

3/13/2015 11:03 am

(Medscape Medical News) Mar 12, 2015 - The National Comprehensive Cancer Network (NCCN) only endorses one genomic test for use in patients with early-stage breast cancer, according to a presenter here at the NCCN 20th Annual Conference.

Lilly Long-acting Insulin Delayed by Liver Concerns

2/23/2015 12:01 pm

(Reuters) Feb 23, 2015 - Eli Lilly and Co said it would postpone by at least two years the marketing application for its once-daily diabetes treatment to evaluate liver concerns, a delay some analysts said could doom the experimental drug.

Lung Cancer ‘Breathalyser' Goes Into Clinical Trials

2/19/2015 12:02 pm

(PharmaTimes [UK]) Feb 15, 2015 - A ground-breaking ‘breath test’ for lung cancer is about to go into clinical trials at Glenfield Hospital in Leicester, UK.

'Window of Vulnerability'

1/29/2015 11:01 am

(Harvard Medical School) Jan 28, 2015 - An existing drug may help some patients with non-small cell lung cancer (NSCLC) whose tumors have become resistant to chemotherapy, according to lab studies by Harvard Medical School researchers at Boston Children’s Hospital and the Dana-Farber Cancer Institute.

How, and Why, Chemists Figured Out How to Unboil an Egg

1/28/2015 12:00 pm

(Washington Post/Speaking of Science) Jan 28, 2015 - The eggs were used as a proxy for a much more serious endeavor: making cancer research more time and cost efficient.

Cancer-fighting CytomX Lands $20 Million Pfizer Investment, Makes Key Hires

1/6/2015 12:00 pm

(San Francisco Business Times) Jan 6, 2015 - CytomX Therapeutics Inc. grabbed $20 million from Pfizer Inc.'s venture capital arm to help partner its sneaky cancer fighters with new types of drugs and build out its own portfolio.

After CAR-T: Getting Ahead of the Next Hot Trend in Cancer Stocks

1/6/2015 12:00 pm

(TheStreet) Jan 6, 2015 - Here's how investors can help fund the next cure for cancer: anti-CD47 antibody therapies.

Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists

9/29/2014 09:05 am

(Cardinal Health) Sept 29, 2014 - Cardinal Health Specialty Solutions and KEW Group, Inc., a privately held oncology services company, today announced an agreement for the two companies to make KEW's state-of-the-art diagnostic services available to Specialty Solutions' community oncology customers.

AbbVie Presents Results From Multiple Studies of Investigational Compound Veliparib in Patients with Non-Small Cell Lung Cancer at the European Society for Medical Oncology Annual Congress

9/29/2014 09:01 am

(CNN Money) Sept 27, 2014 - AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).

ZYTIGA® Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis in Chemotherapy-Naive Men With Metastatic Castration-Resistant Prostate Cancer

9/29/2014 09:01 am

(CNBC) Sept 28, 2014 - A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).